Axcella Health Inc. (AXLA)

Market Cap	1.18M
Revenue (ttm)	n/a
Net Income (ttm)	-50.03M
Shares Out	2.95M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,782
Open	0.360
Previous Close	0.401
Day's Range	0.360 - 0.401
52-Week Range	0.340 - 41.250
Beta	0.58
Analysts	Hold
Price Target	n/a
Earnings Date	Dec 5, 2023

About AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXLA
• Website: https://www.axcellahealth.com